Medición de la calidad de vida por medio del Dermatology Life Quality Index en pacientes con psoriasis: una revisión sistemática
DOI:
https://doi.org/10.29176/2590843X.250Palabras clave:
psoriasis, calidad de vida, reproducibilidad de resultados, impacto de la evaluación de resultadosResumen
Objetivo. Evaluar la calidad de vida relacionada con la salud en pacientes conpsoriasis, por medio del Dermatology Life Quality Index (DLQI).
Metodología. Revisión sistemática de estudios sobre calidad de vida relacionada con la salud en pacientes con psoriasis y en que se haya utilizado el DLQI. La búsqueda incluyó estudios publicados entre el 1994 y el 2012. Se excluyeron los estudios que evaluaran la calidad de vida relacionada con los tratamientos farmacológicos.
Resultados. En ocho estudios se cumplieron los criterios de inclusión y exclusión. Hubo una pérdida de la calidad de vida en los pacientes con psoriasis. El DLQI fue reportado en dos estudios con promedios de 6,4 y 10,8; la duración de la enfermedad varió entre 17,6 y 28,9 años.
Conclusión. La psoriasis afecta la calidad de vida de los pacientes que padecen la enfermedad, tanto en su forma leve como moderada, y este deterioro es superior al encontrado en enfermedades como el acné o el vitiligo.
Biografía del autor/a
Jaime Ordóñez
Investigador de HEMOgroup, Medellín, Colombia
Árlex Palacios
Investigador, Centro de Evaluación de Tecnologías en Salud de la Universidad CES-CETES, Medellín, Colombia
Ángela Londoño
Coordinadora, Grupo de Investigación de Dermatología, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia
Sol Jiménez
Directora, Departamento de Dermatología, Facultad de Medicina, Universidad CES, Medellín, Colombia
Referencias bibliográficas
1. Christophers E. Psoriasis –epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581-8.
3. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-23; quiz 23-26.
4. de Arruda LH, de Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144(Suppl.58):33-6.
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
6. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: Normative data for adults of working age. BMJ. 1993;306:1437-40.
7. Lewis VJ, Finlay AY. A critical review of quality-of-life scales for psoriasis. Dermatol Clin. 2005;23:707-16.
8. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: An holistic measure of psoriasis severity. Br J Dermatol. 2000;142:728-32.
9. McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CEM, et al. Development of the PSORIQoL, a psoriasisspecific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149:323-31.
10. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707-13.
11. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105-10.
12. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales –a measure of the impact of skin diseases. Br J Dermatol. 1997;136:202-6.
13. Schäfer T, Staudt A, Ring J. Development of the German Scale for Assessing Quality of Life in Skin Diseases. Hautarzt. 2001;52:492-8.
14. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433-40.
15. Finlay AY, Kelly SE. Psoriasis –an index of disability. Clin Exp Dermatol. 1987;12:8-11.
16. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: A preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75:240-3.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) –a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
18. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169-80.
19. Lewis VJ, Finlay AY. Two decades experience of the Psoriasis Disability Index. Dermatology (Basel). 2005;210:261-8.
20. Overview and Links | Dermatology Life Quality Index (DLQI). Fecha de consulta: 8 de febrero de 2012. Disponible en: http://www.dermatology.org.uk/quality/dlqi/quality-dlqi.html.
21. Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Kocev N, Tomic-Spiric V, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg. 2011;15:29-36.
22. Rakhesh SV, D’Souza M, Sahai A. Quality of life in psoriasis: A study from south India. Indian J Dermatol Venereol Leprol. 2008;74:600-6.
23. Sampogna F, Tabolli S, Söderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154:844-9.
24. Abolfotouh MA, Al-Khowailed MS, Suliman WE, Al-Turaif DA, Al-Bluwi E, Al-Kahtani HS. Quality of life in patients with skin diseases in central Saudi Arabia. Int J Gen Med. 2012;5:633-42.
25. 25. Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: A comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997-1035.
26. 26. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35.
27. Asawanonda P, Chingchai A, Torranin P. Targeted UV-B phototherapy for plaque-type psoriasis. Arch Dermatol. 2005;141:1542-6.
28. Ortonne J-P, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebocontrolled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol. 2005;5:13.
29. Krueger GG, Langley RG, Finlay AY, Griffiths CEM, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-9.
30. Prins M, Krabbe PFM, Swinkels QOJ, De Boo T, van de Kerkhof PCM, van der Valk PGM. The effect of treatment on quality of life in psoriasis patients. Acta Derm Venereol. 2005;85:304-10.
31. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954-60.
32. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-8.
33. Ricardo RR, Rhoa M, Orenberg EK, Li N, Rundle AC, Caro I. Clinical benefits in patients with psoriasis after efalizumab therapy: Clinical trials versus practice. Cutis. 2004;74:193-200.
34. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-42.
35. van de Kerkhof PCM. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: A randomized controlled trial. Br J Dermatol. 2004;151:663-8.
36. Opmeer BC, Heydendael VMR, De Borgie CAJM, Spuls PI, Bossuyt PMM, Bos JD, et al. Costs of treatment in patients with moderate to severe plaque psoriasis: Economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol. 2004;140:685-90.
37. Fortune DG, Richards HL, Griffiths CEM, Main CJ. Targeting cognitive-behaviour therapy to patients’ implicit model of psoriasis: Results from a patient preference controlled trial. Br J Clin Psychol. 2004;43:65-82.
38. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol.
2004;150:317-26.
39. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003;290:3073-80.
40. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632; discussion 1632.
41. Gordon KB, Vaishnaw AK, O’Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003;139:1563-70.
42. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: A randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis. 2003;72:407-11.
43. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
44. Heydendael VMR, Spuls PI, Opmeer BC, De Borgie CAJM, Reitsma JB, Goldschmidt WFM, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med.
2003;349:658-65.
45. Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial. Br J Dermatol. 2003;149:146-50.
46. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003;49:79-82.
47. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstädter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: Sensitive to changes of quality of life in psoriasis patients? Br J Dermatol. j 2003;148:1153-60.
48. Ortonne J-P. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(Suppl.2):12-6.
49. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology (Basel). 2003;206:307-15.
50. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on healthrelated quality of life in patients with psoriasis: Results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4:131-9.
51. Gradwell C, Thomas KS, English JSC, Williams HC. A randomized controlled trial of nurse follow-up clinics: Do they help patients and do they free up consultants’ time? Br J Dermatol. 2002;147:513-7.
52. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CEM. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146:458-65.
53. Touw CR, Hakkaart-van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144:967-72.
54. James M. A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis. Cutis. 2001;67(Suppl.):2-9.
55. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. J Am Acad Dermatol. 2001;44:643-51.
56. Leonardi CL. Efalizumab: An overview. J Am Acad Dermatol. 2003;49(Suppl.):S98-104.
57. Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol. 2010;49:1368-75.
58. Aghaei S, Moradi A, Ardekani GS. Impact of psoriasis on quality of life in Iran. Indian J Dermatol Venereol Leprol. 2009;75:220.
59. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: Data from Danish inpatients and outpatients. Acta Derm Venereol. 2000;80:272-6.
60. Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol. 2005;85:409-13.
61. Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: Cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4:559-68.
62. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040-7.
63. Chernyshov PV, Bylatte M. Comparative study of quality of life in patients with psoriasis from Lithuania and Ukraine. Lik Sprava. 2010; 7-8:107-11.
64. Sato R, Milligan G, Molta C, Singh A. Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: An association independent of observed disease severity. Clin Exp Dermatol. 2011;36:24-8.
65. Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75:551.
66. Wahl AK, Mørk C, Lillehol BM, Myrdal AM, Helland S, Hanestad BR, et al. Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology. Acta Derm Venereol. 2006;86:198-201.
67. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149:318-22.
68. Lin T-Y, See L-C, Shen Y-M, Liang C-Y, Chang H-N, Lin Y-K. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011;34:186-96.
69. Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology (Basel). 2009;219:54-8.
70. Nijsten T, Meads DM, De Korte J, Sampogna F, Gelfand JM, Ongenae K, et al. Cross-cultural inequivalence of dermatologyspecific health-related quality of life instruments in psoriasis patients. J Invest Dermatol. 2007;127:2315-22.
71. Badia X, Mascaró JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141:698-702.
72. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: Results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
73. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
74. Mørk C, Wahl A. Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands. J Am Acad Dermatol. 2002;47:314-6.
75. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol. 2004;3:27-38.
76. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-7.
77. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-tomoderate psoriasis. Pharmacoeconomics. 1996;10:644-53.
78. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: A cluster analysis. J Invest Dermatol. 2004;122:602-7.
79. McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: A psoriasis-specific measure of quality of life. Int J Dermatol. 2005;44:462-9.
80. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology (Basel). 2007;215:17-27.
81. Schmitt J, Heese E, Wozel G, Meurer M. Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris –a prospective study. Dermatology (Basel). 2007;214:68-76.
82. Schmid-Ott G, Burchard R, Niederauer HH, Lamprecht F, Künsebeck H-W. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis. Hautarzt. 2003;54:852-7.
83. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W-H. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges. 2007;5:762-8.
84. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multi-center study. J Dtsch Dermatol Ges. 2007;5:209-18.
85. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Quality of life in skin diseases: Methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt. 1999;50:715-22.
86. Antoniou C, Stefanaki I, Stratigos A, Avgerinou G, Stavropoulos P, Potouridou I, et al. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol. 2007;156(Suppl.2):12-6.
87. Sampogna F, Gisondi P, Tabolli S, Abeni D. Impairment of sexual life in patients with psoriasis. Dermatology (Basel). 2007;214:144-50.
88. De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. Highdose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients’ quality of life. J Dermatolog Treat. 2006;17:355-8.
89. Papoutsaki M, Chimenti M-S, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269-75.
90. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study. J Am Acad Dermatol. 2006;54:1013-8.
91. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: A systematic review. Health Technol Assess. 2006;10:1-233, i-iv.
92. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: A randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2006;154:1169-74.
93. Smith CH, Jackson K, Bashir SJ, Pérez A, Chew AL, Powell AM, et al. Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study. Br J Dermatol. 2006;155:160-9.
94. Vensel E, Hilley T, Trent J, Taylor JR, Kirsner RS, Kerdel FA, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 2000;43:858-60.
95. Gottlieb AB, Mease PJ, Mark Jackson J ¿?, Eisen D, Amy Xia H, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat. 2006;17:279-87.
96. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol. 2005;152:1256-62.
97. Wahl AK, Mørk C, Hanestad BR, Helland S. Coping with exacerbation in psoriasis and eczema prior to admission in a dermatological ward. Eur J Dermatol. 2006;16:271-5.
98. Uttjek M, Dufåker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84:37-43.
99. Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-14.
100. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156:1245-50.
101. Türel Ermertcan A, Temelta G, Deveci A, Dinç G, Güler HB, Oztürkcan S. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33:772-8.
102. Al-Mazeedi K, El-Shazly M, Al-Ajmi HS. Impact of psoriasis on quality of life in Kuwait. Int J Dermatol. 2006;45:418-24.
103. Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154:325-31.
104. De Jager MEA, De Jong EMGJ, van der Kerkhof PCM, Evers AWM, Seyger MMB. An intrapatient comparison of quality of life in psoriasis in childhood and adulthood. J Eur Acad Dermatol Venereol. 2011;25:828-31.
105. Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: An epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075-82.
106. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology (Basel). 2006;213:102-10.
107. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology (Basel). 2008;216:366-72.
108. Augustin M, Reich K, Reich C, Purwins S, J Rustenbach J, Schäfer I, et al. Quality of psoriasis care in Germany –results of the national study PsoHealth 2007. J Dtsch Dermatol Ges. 2008;6:640-5.
109. Meeuwis KAP, De Hullu JA, van de Nieuwenhof HP, Evers AWM, Massuger LFAG, van de Kerkhof PCM, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164:1247-55.
110. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430-4.
111. Schäfer T, Staudt A, Ring J. German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Hautarzt. 2001;52:624-8.
112. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37:41-50.
113. Finlay AY, Kelly SE. Psoriasis –an index of disability. Clin Exp Dermatol. 1987;12:8-11.
114. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236-44.
115. Both H, Essink-Bot M-L, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127:2726-39.
116. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud P-A, Aractingi S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl.2):17-22.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581-8.
3. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-23; quiz 23-26.
4. de Arruda LH, de Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144(Suppl.58):33-6.
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
6. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: Normative data for adults of working age. BMJ. 1993;306:1437-40.
7. Lewis VJ, Finlay AY. A critical review of quality-of-life scales for psoriasis. Dermatol Clin. 2005;23:707-16.
8. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: An holistic measure of psoriasis severity. Br J Dermatol. 2000;142:728-32.
9. McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CEM, et al. Development of the PSORIQoL, a psoriasisspecific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149:323-31.
10. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707-13.
11. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105-10.
12. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales –a measure of the impact of skin diseases. Br J Dermatol. 1997;136:202-6.
13. Schäfer T, Staudt A, Ring J. Development of the German Scale for Assessing Quality of Life in Skin Diseases. Hautarzt. 2001;52:492-8.
14. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433-40.
15. Finlay AY, Kelly SE. Psoriasis –an index of disability. Clin Exp Dermatol. 1987;12:8-11.
16. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: A preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75:240-3.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) –a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
18. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169-80.
19. Lewis VJ, Finlay AY. Two decades experience of the Psoriasis Disability Index. Dermatology (Basel). 2005;210:261-8.
20. Overview and Links | Dermatology Life Quality Index (DLQI). Fecha de consulta: 8 de febrero de 2012. Disponible en: http://www.dermatology.org.uk/quality/dlqi/quality-dlqi.html.
21. Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Kocev N, Tomic-Spiric V, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg. 2011;15:29-36.
22. Rakhesh SV, D’Souza M, Sahai A. Quality of life in psoriasis: A study from south India. Indian J Dermatol Venereol Leprol. 2008;74:600-6.
23. Sampogna F, Tabolli S, Söderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154:844-9.
24. Abolfotouh MA, Al-Khowailed MS, Suliman WE, Al-Turaif DA, Al-Bluwi E, Al-Kahtani HS. Quality of life in patients with skin diseases in central Saudi Arabia. Int J Gen Med. 2012;5:633-42.
25. 25. Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: A comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997-1035.
26. 26. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35.
27. Asawanonda P, Chingchai A, Torranin P. Targeted UV-B phototherapy for plaque-type psoriasis. Arch Dermatol. 2005;141:1542-6.
28. Ortonne J-P, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebocontrolled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol. 2005;5:13.
29. Krueger GG, Langley RG, Finlay AY, Griffiths CEM, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-9.
30. Prins M, Krabbe PFM, Swinkels QOJ, De Boo T, van de Kerkhof PCM, van der Valk PGM. The effect of treatment on quality of life in psoriasis patients. Acta Derm Venereol. 2005;85:304-10.
31. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954-60.
32. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-8.
33. Ricardo RR, Rhoa M, Orenberg EK, Li N, Rundle AC, Caro I. Clinical benefits in patients with psoriasis after efalizumab therapy: Clinical trials versus practice. Cutis. 2004;74:193-200.
34. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-42.
35. van de Kerkhof PCM. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: A randomized controlled trial. Br J Dermatol. 2004;151:663-8.
36. Opmeer BC, Heydendael VMR, De Borgie CAJM, Spuls PI, Bossuyt PMM, Bos JD, et al. Costs of treatment in patients with moderate to severe plaque psoriasis: Economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol. 2004;140:685-90.
37. Fortune DG, Richards HL, Griffiths CEM, Main CJ. Targeting cognitive-behaviour therapy to patients’ implicit model of psoriasis: Results from a patient preference controlled trial. Br J Clin Psychol. 2004;43:65-82.
38. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol.
2004;150:317-26.
39. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003;290:3073-80.
40. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632; discussion 1632.
41. Gordon KB, Vaishnaw AK, O’Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003;139:1563-70.
42. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: A randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis. 2003;72:407-11.
43. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
44. Heydendael VMR, Spuls PI, Opmeer BC, De Borgie CAJM, Reitsma JB, Goldschmidt WFM, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med.
2003;349:658-65.
45. Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial. Br J Dermatol. 2003;149:146-50.
46. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003;49:79-82.
47. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstädter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: Sensitive to changes of quality of life in psoriasis patients? Br J Dermatol. j 2003;148:1153-60.
48. Ortonne J-P. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(Suppl.2):12-6.
49. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology (Basel). 2003;206:307-15.
50. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on healthrelated quality of life in patients with psoriasis: Results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4:131-9.
51. Gradwell C, Thomas KS, English JSC, Williams HC. A randomized controlled trial of nurse follow-up clinics: Do they help patients and do they free up consultants’ time? Br J Dermatol. 2002;147:513-7.
52. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CEM. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146:458-65.
53. Touw CR, Hakkaart-van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144:967-72.
54. James M. A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis. Cutis. 2001;67(Suppl.):2-9.
55. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. J Am Acad Dermatol. 2001;44:643-51.
56. Leonardi CL. Efalizumab: An overview. J Am Acad Dermatol. 2003;49(Suppl.):S98-104.
57. Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol. 2010;49:1368-75.
58. Aghaei S, Moradi A, Ardekani GS. Impact of psoriasis on quality of life in Iran. Indian J Dermatol Venereol Leprol. 2009;75:220.
59. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: Data from Danish inpatients and outpatients. Acta Derm Venereol. 2000;80:272-6.
60. Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol. 2005;85:409-13.
61. Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: Cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4:559-68.
62. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040-7.
63. Chernyshov PV, Bylatte M. Comparative study of quality of life in patients with psoriasis from Lithuania and Ukraine. Lik Sprava. 2010; 7-8:107-11.
64. Sato R, Milligan G, Molta C, Singh A. Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: An association independent of observed disease severity. Clin Exp Dermatol. 2011;36:24-8.
65. Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75:551.
66. Wahl AK, Mørk C, Lillehol BM, Myrdal AM, Helland S, Hanestad BR, et al. Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology. Acta Derm Venereol. 2006;86:198-201.
67. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149:318-22.
68. Lin T-Y, See L-C, Shen Y-M, Liang C-Y, Chang H-N, Lin Y-K. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011;34:186-96.
69. Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, et al. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology (Basel). 2009;219:54-8.
70. Nijsten T, Meads DM, De Korte J, Sampogna F, Gelfand JM, Ongenae K, et al. Cross-cultural inequivalence of dermatologyspecific health-related quality of life instruments in psoriasis patients. J Invest Dermatol. 2007;127:2315-22.
71. Badia X, Mascaró JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141:698-702.
72. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: Results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
73. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
74. Mørk C, Wahl A. Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands. J Am Acad Dermatol. 2002;47:314-6.
75. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol. 2004;3:27-38.
76. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-7.
77. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-tomoderate psoriasis. Pharmacoeconomics. 1996;10:644-53.
78. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: A cluster analysis. J Invest Dermatol. 2004;122:602-7.
79. McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: A psoriasis-specific measure of quality of life. Int J Dermatol. 2005;44:462-9.
80. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology (Basel). 2007;215:17-27.
81. Schmitt J, Heese E, Wozel G, Meurer M. Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris –a prospective study. Dermatology (Basel). 2007;214:68-76.
82. Schmid-Ott G, Burchard R, Niederauer HH, Lamprecht F, Künsebeck H-W. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis. Hautarzt. 2003;54:852-7.
83. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W-H. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges. 2007;5:762-8.
84. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multi-center study. J Dtsch Dermatol Ges. 2007;5:209-18.
85. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Quality of life in skin diseases: Methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt. 1999;50:715-22.
86. Antoniou C, Stefanaki I, Stratigos A, Avgerinou G, Stavropoulos P, Potouridou I, et al. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol. 2007;156(Suppl.2):12-6.
87. Sampogna F, Gisondi P, Tabolli S, Abeni D. Impairment of sexual life in patients with psoriasis. Dermatology (Basel). 2007;214:144-50.
88. De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. Highdose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients’ quality of life. J Dermatolog Treat. 2006;17:355-8.
89. Papoutsaki M, Chimenti M-S, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269-75.
90. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study. J Am Acad Dermatol. 2006;54:1013-8.
91. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: A systematic review. Health Technol Assess. 2006;10:1-233, i-iv.
92. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: A randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2006;154:1169-74.
93. Smith CH, Jackson K, Bashir SJ, Pérez A, Chew AL, Powell AM, et al. Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study. Br J Dermatol. 2006;155:160-9.
94. Vensel E, Hilley T, Trent J, Taylor JR, Kirsner RS, Kerdel FA, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 2000;43:858-60.
95. Gottlieb AB, Mease PJ, Mark Jackson J ¿?, Eisen D, Amy Xia H, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat. 2006;17:279-87.
96. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol. 2005;152:1256-62.
97. Wahl AK, Mørk C, Hanestad BR, Helland S. Coping with exacerbation in psoriasis and eczema prior to admission in a dermatological ward. Eur J Dermatol. 2006;16:271-5.
98. Uttjek M, Dufåker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84:37-43.
99. Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-14.
100. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156:1245-50.
101. Türel Ermertcan A, Temelta G, Deveci A, Dinç G, Güler HB, Oztürkcan S. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33:772-8.
102. Al-Mazeedi K, El-Shazly M, Al-Ajmi HS. Impact of psoriasis on quality of life in Kuwait. Int J Dermatol. 2006;45:418-24.
103. Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154:325-31.
104. De Jager MEA, De Jong EMGJ, van der Kerkhof PCM, Evers AWM, Seyger MMB. An intrapatient comparison of quality of life in psoriasis in childhood and adulthood. J Eur Acad Dermatol Venereol. 2011;25:828-31.
105. Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: An epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075-82.
106. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology (Basel). 2006;213:102-10.
107. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology (Basel). 2008;216:366-72.
108. Augustin M, Reich K, Reich C, Purwins S, J Rustenbach J, Schäfer I, et al. Quality of psoriasis care in Germany –results of the national study PsoHealth 2007. J Dtsch Dermatol Ges. 2008;6:640-5.
109. Meeuwis KAP, De Hullu JA, van de Nieuwenhof HP, Evers AWM, Massuger LFAG, van de Kerkhof PCM, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164:1247-55.
110. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430-4.
111. Schäfer T, Staudt A, Ring J. German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Hautarzt. 2001;52:624-8.
112. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37:41-50.
113. Finlay AY, Kelly SE. Psoriasis –an index of disability. Clin Exp Dermatol. 1987;12:8-11.
114. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236-44.
115. Both H, Essink-Bot M-L, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127:2726-39.
116. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud P-A, Aractingi S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl.2):17-22.
Cómo citar
1.
Ordóñez J, Palacios Árlex, Londoño Ángela, Jiménez S. Medición de la calidad de vida por medio del Dermatology Life Quality Index en pacientes con psoriasis: una revisión sistemática. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de octubre de 2013 [citado 19 de abril de 2024];21(4):305-13. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/250
Descargas
Los datos de descargas todavía no están disponibles.
Descargas
Publicado
2013-10-01
Cómo citar
1.
Ordóñez J, Palacios Árlex, Londoño Ángela, Jiménez S. Medición de la calidad de vida por medio del Dermatology Life Quality Index en pacientes con psoriasis: una revisión sistemática. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de octubre de 2013 [citado 19 de abril de 2024];21(4):305-13. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/250
Número
Sección
Artículo de investigación
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
